Curaleaf CURLF Q2 2026 10-Q: The Aurora Takeover Bid Math and the $468M 280E Reserve
Listen to this report
RoboSystems Coverage Update · Curaleaf Holdings, Inc. · OTCQX: CURLF / TSX: CURA · Q2 2026 Form 10-Q (accession 0001756770-26-000075, filed August 6, 2026) · Published August 16, 2026
The Hook
Last quarter we covered Curaleaf $CURLF and said the largest US cannabis company by revenue had reported its best-ever quarterly profit while actually losing money, because the entire profit was an income tax benefit. This quarter it did the same thing again, at a quarter of the size. But that is no longer the story.
Here is the story. For the six months ended June 30, 2026, Curaleaf generated $664.3 million of revenue and $4.975 million of operating income. Not four hundred and ninety-seven million. Four point nine seven five million dollars, on a business the size of a mid-cap consumer packaged goods company. That is three quarters of one cent of operating profit per dollar of sales, and it is down 68 percent from the $15.6 million it earned in the same half of 2025. Five days after filing that 10-Q, on August 11, 2026, Curaleaf announced it would take a hostile take-over bid directly to Aurora Cannabis shareholders, at a total implied value of about $272 million.
The interesting question is not whether Curaleaf can afford the cash. It can, easily. The interesting question is what the filing says about why the offer is 81 percent stock.
Company Snapshot
Curaleaf is the largest US multi-state cannabis operator by revenue and, on its own claim, the largest cannabis operator globally. As of June 30, 2026 it ran 173 owned and managed dispensaries across 14 states and served over 1,300 wholesale accounts, and its brands reached medical patients in 15 countries outside the US, headlined by Germany, the UK, Poland and Australasia. It cultivates on 18 sites with roughly 1.5 million square feet of capacity, with EU-GMP certified manufacturing in Canada, Germany, Portugal, Spain and the UK.
This is the first quarter Curaleaf has filed as a US domestic issuer. Its prior annual reports were 40-Fs under the Canadian MJDS regime, so this Form 10-Q, filed August 6, 2026 for the period ended June 30, 2026, is a genuinely new level of disclosure for the name. Everything below comes out of it.
The Financial Story
The top line is fine. Revenue rose 9.5 percent to $340.1 million in the quarter and 7.6 percent to $664.3 million for the half. Gross margin actually improved, to 50.0 percent from 49.3 percent. International revenue grew 26 percent in the quarter and 30 percent for the half. On a headline read, Curaleaf is growing again after three flat years.
Then look at what arrived at the bottom. For the six months, Adjusted EBITDA was $133.5 million against $134.0 million a year earlier. Revenue up $47.1 million; Adjusted EBITDA down $0.4 million. Every dollar of incremental revenue and then some was consumed by operating expense, which rose from $146.8 million to $165.7 million in the quarter alone. Operating income for the half fell to $4.975 million. Below that line sits $52.9 million of net interest expense for the half, which is where the pre-tax loss of $54.9 million comes from.
| Six months ended June 30 | 2025 | 2026 | Change |
|---|---|---|---|
| Revenue, net | $617.2M | $664.3M | +7.6% |
| Gross profit | $308.7M | $327.2M | +6.0% |
| Operating income | $15.6M | $5.0M | -68.1% |
| Adjusted EBITDA | $134.0M | $133.5M | -0.3% |
| Interest expense, net | $50.6M | $52.9M | +4.5% |
| Pre-tax loss, continuing ops | ($32.7M) | ($54.9M) | worse by $22.3M |
| Income tax expense (benefit) | $65.5M | ($137.5M) | swing of $203.0M |
| Net income (loss) | ($114.2M) | $82.3M | swing of $196.5M |
The $82.3 million of reported net income is entirely the tax line. Pre-tax, Curaleaf lost $54.9 million in the first half of 2026, which is $22.3 million worse than the first half of 2025. The $137.5 million benefit is what turned that into a profit, and it is not one thing. In the second quarter specifically, the $38.8 million benefit came from releasing $65.1 million of valuation allowance against US deferred tax assets, partially offset by an additional $31.5 million of Section 280E liability and interest that Curaleaf accrued in the same quarter. In other words: the uncertain tax position reserve fell $63.0 million over the half, but $94.5 million of that release happened in Q1 and the second quarter went the other way.
Note the distinction carefully, because it is the whole game with this company: that $137.5 million is an accounting benefit, not cash. Cash income taxes paid in the first half were $5.4 million.
Now the cash. Operating cash flow for the half was $50.2 million. Capital expenditure was $32.9 million. Free cash flow was $17.4 million. Cash interest paid was $50.5 million, roughly three times the free cash flow it produced. Cash and equivalents ended the quarter at $94.6 million, plus $12.4 million restricted. Against that, the filing's own contractual obligations table totals $2.074 billion, of which $174.2 million comes due inside twelve months.
The debt is the part that decides everything else. In February 2026 Curaleaf privately placed $500.0 million of Senior Secured Notes at an 11.50 percent coupon (12.16 percent effective) due February 18, 2029, and used the proceeds to retire the 2026 notes. Total notes payable principal is $619.3 million, and $553.3 million of it matures in a single year: 2029.
| Fiscal year | Notes payable maturing |
|---|---|
| 2026 (six months remaining) | $28.7M |
| 2027 | $31.0M |
| 2028 | $1.4M |
| 2029 | $553.3M |
| 2030 and thereafter | $4.8M |
| Total | $619.3M |
The Correction: This Is Not a Funding Problem, and It Is Not About Countries
We were sent into this filing to test whether Curaleaf can pay for Aurora. On the numbers, the answer is yes, and the assigned framing was wrong on both halves. Both corrections are more interesting than the thesis.
First, the cash is trivial. Aurora's FY2026 40-F (year ended March 31, 2026, filed June 11, 2026) reports 58,947,593 shares issued and fully paid. At the announced US$0.75 per share cash component, that is about $44 million. Press coverage sizing the deal at roughly $272 million implies a share count nearer 68 million and a cash component nearer $51 million. Either figure sits comfortably inside Curaleaf's $94.6 million of cash, before touching the $46.3 million of unused capacity on its Needham credit line. The share component, 0.3463 Curaleaf shares per Aurora share, is about 20 to 24 million new shares against 264.7 million outstanding: roughly 8 percent dilution. This is not a company stretching to write a check.
So why is the offer only 18.75 percent cash? Because the filing shows Curaleaf cannot borrow. The 2029 indenture permits additional debt only if, pro forma, the consolidated fixed charge coverage ratio is at least 2.5 to 1 and consolidated indebtedness to consolidated EBITDA does not exceed 4 to 1. On Curaleaf's own reported figures for the first half, Adjusted EBITDA of $133.5 million against net interest expense of $52.9 million is 2.53 times. That is on the line. Add the finance leases ($167.7 million) and the failed-sale-leaseback financial obligations ($205.6 million) to the $619.3 million of notes and total obligations reach $992.5 million, or 3.7 times annualized Adjusted EBITDA of $267.1 million, against a 4 to 1 ceiling. The indenture's own definitions of consolidated EBITDA and fixed charges will differ from the reported figures, so treat these as directional. The direction is not ambiguous. Curaleaf is paying in shares because shares are the only currency the indenture does not govern.
Second, this is not a bid for someone else's international footprint. Curaleaf already has the biggest one in the industry. The 10-Q says its brands reach medical patients in 15 countries outside the United States. Add the US and Curaleaf is already at 16. The announced rationale for the bid is a combined footprint spanning 17 countries. That is one additional country. The press release also cites Aurora's EU-GMP certified cultivation and manufacturing; Curaleaf's own filing lists EU-GMP compliant facilities in Canada, Germany, Portugal, Spain and the UK, and describes its Canadian subsidiary's EU-GMP2 certification as "critical to our European supply chain strategy." What Aurora adds is capacity and Canadian scale, not capability and not geography.
What the deal actually is, on the arithmetic: an equity arbitrage. Curaleaf closed at $9.38 on August 10, 2026, the day before the announcement, for a market capitalization near $2.48 billion and an enterprise value around $3.0 billion, or about 2.3 times annualized revenue. Aurora reported $320.6 million of net revenue in its FY2026 40-F, so a $272 million bid values it near 0.85 times sales. Curaleaf is buying revenue at 0.85 times with paper the market prices at 2.3 times. That trade works. Whether it should is a separate question, because Aurora also reported a net loss of $136.0 million for that year and negative $13.5 million of operating cash flow, and its cash fell from $137.9 million to $64.7 million over twelve months.
A boundary worth stating plainly: none of the bid terms are in the 10-Q. The filing predates the announcement by five days. Its subsequent-events note discloses a $13.0 million retail acquisition signed July 16, 2026 and the July 1 closing of RC Retail 2, and nothing about Aurora. Every bid figure here comes from Curaleaf's August 11 press release and contemporaneous coverage, not from the filing.
Catalyst Scenarios: How the Math Changes
The rescheduling catalyst is real and it is half-fired, and the 10-Q is the first filing that shows what partial relief actually does. Effective April 23, 2026, state-licensed medical and FDA-approved marijuana moved to Schedule III; adult-use did not. Curaleaf concluded that from that date Section 280E no longer limits deductions on its qualifying medical activity, and stopped recording new uncertain tax positions against it. That is why the valuation allowance came down.
What did not happen: the reserve did not go away. The uncertain tax position liability stands at $468.5 million as of June 30, 2026, down $63.0 million over six months, and Curaleaf added $31.5 million of liability and interest back in the second quarter alone because adult-use activity is still Schedule I. Curaleaf is under IRS audit for tax years 2020 through 2024. Treasury and the IRS have issued no formal guidance on the rescheduling order's tax mechanics; the filing says the company "applied its interpretation."
| Scenario | What happens to the reserve | Rough effect |
|---|---|---|
| Status quo (medical-only relief) | Continues accruing on adult-use, roughly $31.5M per quarter | $468.5M liability persists and grows |
| Broad Schedule III, prospective only | New accruals stop; back years unresolved | Removes roughly $126M a year of accrual pressure |
| Broad Schedule III with retroactive relief | Reserve released | $468.5M, or 54% of the $867.5M equity base and 19% of market cap |
The company's own risk factors name the mechanism: if the proposed rule is adopted it "would clarify that Section 280E does not apply to our operations more broadly, which could result in a material reduction in our uncertain tax positions." That is the single largest swing factor in the equity, and it is worth more than the Aurora deal by a factor of roughly two.
On consolidation, the read from this filing is that Curaleaf is a buyer with a specific constraint. It signed $13.0 million of retail acquisitions in July, bought in the remaining 45 percent of its German subsidiary Four20 Pharma on April 30 for 10,419,261 shares, and is now bidding for Aurora with 81 percent stock. Note the tell: Curaleaf's normal course issuer bid authorizes it to repurchase up to 11,462,943 shares between April 2026 and April 2027. It has bought 93,363. It is not retiring shares. It is spending them.
Valuation: What It Is Worth If It Is a Normal Business
Anchors first. At $9.38 on August 10, 2026, market capitalization is roughly $2.48 billion. Adding the $619.3 million of notes and subtracting $94.6 million of cash gives an enterprise value near $3.01 billion, or 11.3 times annualized first-half Adjusted EBITDA of $267.1 million. Include the finance leases and the failed-sale-leaseback obligations and enterprise value is roughly $3.38 billion, or 12.7 times. That is the same 12 to 13 times range we noted last quarter.
Base case, 280E persists and the bid fails. Adjusted EBITDA holds near $267 million, free cash flow runs near $35 million a year against roughly $101 million of annual cash interest, and the $468.5 million reserve keeps accruing. On a 8 to 10 times EV to EBITDA multiple, discounted from the 10 to 14 times where CPG and health-and-wellness peers trade to reflect Schedule I risk, an OTC listing and a 2029 refinancing wall, enterprise value is $2.14 billion to $2.67 billion. Net of $524.7 million of net notes debt, equity is $1.61 billion to $2.15 billion, or roughly $6.10 to $8.10 per share on 264.7 million shares.
Full-catalyst case, broad Schedule III with retroactive relief. The $468.5 million reserve releases, the tax drag on adult-use income ends, and the multiple re-rates toward the peer band at 12 to 14 times. Enterprise value of $3.20 billion to $3.74 billion, plus the $468.5 million reserve release, less net debt, gives equity of $3.15 billion to $3.68 billion, or roughly $11.90 to $13.90 per share.
Today's $9.38 sits above the top of the base band and below the bottom of the catalyst band. Read literally, the market is pricing in a partial win: some probability that broad rescheduling lands, discounted for the possibility it does not. That is a defensible place for the price to be, and it is also why paying in stock at this level is rational for management and expensive for anyone holding shares if the catalyst does not fire. These are implied values under the stated assumptions, not price targets, and not advice.
Risks and Open Questions
The dominant risk is that the rescheduling process stalls. The DEA's broader hearing concluded in July 2026 but the ALJ recommendation has not issued, a final determination is expected late 2026 or early 2027, and the April partial order faces a pending D.C. Circuit challenge. If broad Schedule III does not arrive, the $468.5 million reserve stays on the balance sheet and keeps compounding at roughly $31.5 million a quarter, against $867.5 million of book equity and $94.6 million of cash.
Second, the 2029 wall. $553.3 million matures in a single year at an 11.50 percent coupon, and the company generated $17.4 million of free cash flow in six months. That will be refinanced, not repaid, and the terms will depend on where cannabis credit trades in 2028.
Third, the Aurora bid is hostile and unsolicited. Aurora has declined to engage since Boris Jordan's June 23 letter of intent. A bid taken directly to shareholders can fail, can be topped, or can be repriced, and the share-exchange ratio is fixed while both stocks move. It also consumes management attention at a company whose domestic Adjusted EBITDA just went sideways.
Fourth, the operating trend itself. Domestic segment Adjusted EBITDA was $63.5 million this quarter against $63.9 million a year ago. Domestic retail revenue grew 4 percent while the filing attributes the growth to new store openings, "partially offset by price compression due to increased competition." The growth is coming from opening doors, not from the doors already open.
The Bottom Line
Curaleaf's business is bigger than it was a year ago and no more profitable. Revenue grew $47.1 million in the first half; Adjusted EBITDA fell $0.4 million; operating income fell to $4.975 million; the reported profit was a tax entry. The one thing on Curaleaf's balance sheet that got materially more valuable in 2026 is its own stock, and the takeover bid for Aurora is what spending that appreciation looks like. The offer is 81 percent stock not because Curaleaf lacks $51 million of cash, but because its 2029 indenture caps new borrowing at a 2.5 to 1 fixed charge coverage test that its own reported numbers clear by three hundredths of a turn.
And the strategic rationale is thinner than advertised. Curaleaf already reaches patients in 15 countries outside the US and already runs EU-GMP facilities in five. A combined 17-country footprint adds one country. What it adds in substance is Aurora's Canadian cultivation scale and roughly $321 million of revenue bought at 0.85 times sales with paper trading at 2.3 times.
Watch four things, in order: the ALJ recommendation and the DEA Administrator's final rule, because that reserve is worth roughly twice the deal; whether Treasury issues tax guidance that validates or reverses Curaleaf's interpretation; whether Aurora's board engages or entrenches; and the Q3 print, where the test is whether Adjusted EBITDA finally moves with revenue. The framework, not the recommendation.
Every figure attributed to the filing comes from Curaleaf Holdings' Form 10-Q for the quarter ended June 30, 2026 (CIK 0001756770, accession 0001756770-26-000075, filed August 6, 2026), read through the RoboSystems SEC Shared Repository. Aurora Cannabis figures come from its Form 40-F for the fiscal year ended March 31, 2026 (CIK 0001683541, filed June 11, 2026). The take-over bid terms are announced terms from Curaleaf's August 11, 2026 press release and contemporaneous news coverage, not filing facts; the 10-Q predates the announcement and does not mention it. Share price as of August 10, 2026. This is not investment advice, and no price targets are offered.
This analysis was built on the RoboSystems SEC Shared Repository: structured, queryable filing data for every public company that files. Get started at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.